A meta-analysis of more than 80 studies from the past four decades finds weak evidence to support the use of medicinal cannabis to treat anxiety, depression, and other mental health disorders.

Recent federal announcements serve as reminders that in the US policy continues to outpace science when it comes to cannabis.

The federal government cautions that the drug can affect brain development in both teens and fetuses.

A Novartis subsidiary is partnering with a Canadian cannabis company to sell medical marijuana worldwide.

The country is the second in Africa to permit cannabis cultivation, but months after approval there’s been little uptake by farmers and no scientific proposals.

The coming legalization of recreational marijuana is already increasing funding for studies, but regulations on such research have been slow to change.

As the CBD-based medication enters the market, the agency promises a crackdown on producers of cannabidiol products that make unproven claims.

Around 40 percent of children with an uncommon disorder had 50 percent fewer seizures while taking the marijuana derivative.

In young mice, THC had the opposite effect.

US scientists continue to have a hard time getting funding to study the health impacts of the drug. But cannabis research in Canada—where medical marijuana is legal nationwide—is different story.

A new report summarizes what we know about the impacts of marijuana use, as more states have legalized the drug for both medical and recreational purposes.

Science under Trump, gene drive, medical marijuana, and more

Stoned, Anxious, The Deeper Genome, and Testosterone

Scientists wishing to study marijuana’s health effects may now forgo a review by Public Health Services.

The dosage information on 83 percent of 75 edible marijuana products legally sold in Seattle, San Francisco, and Los Angeles was incorrect.

The marijuana-derived compound shows promise in treating rare forms of epilepsy that cause children to have seizures multiple times a day.

As more states legalize therapeutic cannabis, some caution against overprescribing the drug, the benefits of which have not been rigorously tested in clinical trials.

Addiction is one among many potential adverse effects of the increasingly popular drug, according to the National Institute on Drug Abuse.

A pro-pot group airs an ad stating marijuana is “less toxic” than alcohol, but a federal science agency disputes the assertion.